What is a Peptide Certificate of Analysis (COA)?
September 16, 2026
A Peptide Certificate of Analysis (COA) is a document that reports analytical testing performed on
A Peptide Certificate of Analysis (COA) is a document that reports analytical testing performed on a specific peptide sample or batch. For researchers, a COA can provide important information about the material being evaluated, including its identity, reported purity, batch or lot number, analytical methods, testing date, and laboratory information.
According to the FDA’s ICH Q7 guidance, an authentic certificate of analysis for an active pharmaceutical ingredient should identify the material and batch, list the tests performed and acceptance criteria, and provide the numerical results where applicable.
At Neuro Peptides, we recognize a COA as an important part of research-material documentation. However, a COA should be interpreted as analytical evidence for a particular material and batch—not simply as a marketing document or a guarantee of every possible quality attribute.
A COA typically connects a tested material to a particular product and batch or lot. Important information may include the peptide name, batch number, date of release or testing, analytical methods, test results, acceptance criteria, and the identity of the testing laboratory.
The importance of batch traceability is emphasized in FDA’s ICH Q7 guidance, which states that certificates should identify the material and batch and list the tests performed, acceptance limits, and numerical results. FDA also recommends periodically checking the reliability of supplier certificates through appropriate testing.
Researchers should therefore ask a basic question before evaluating any result: Does this COA actually correspond to the batch being considered? A certificate with no batch or lot identifier provides much less evidence about a specific vial than a batch-linked report.
High-performance liquid chromatography (HPLC) is commonly used to evaluate the chromatographic purity of peptide materials. In an HPLC analysis, different components can separate based on their interactions with the chromatographic system, producing peaks that can be evaluated as part of the purity assessment.
A reported HPLC purity percentage should therefore be interpreted in the context of the analytical method and chromatogram. A high percentage does not, by itself, establish molecular identity, sterility, endotoxin status, or the exact amount of peptide in a vial.
Recent peer-reviewed research demonstrates why chromatographic results should be interpreted in the context of the analytical system and method. Streuli et al. (2026) reported that peptide purification and purity control can be affected by analytical conditions and system differences, emphasizing the importance of robust analytical methods when evaluating synthetic peptides.
Mass spectrometry (MS) answers a different analytical question from HPLC. Rather than primarily measuring chromatographic separation, MS measures molecular mass and can provide evidence supporting the identity and integrity of a synthetic peptide.
A recent scientific review of synthetic-peptide characterization states that mass spectrometry is an important method for evaluating peptide authenticity and integrity.
This distinction is important when reading a peptide COA. HPLC purity and mass spectrometry identity are complementary pieces of information, not interchangeable tests. A COA reporting only an HPLC purity value leaves the identity question less completely addressed than a report that also provides appropriate identity data.
The batch or lot number is one of the most important identifiers on a peptide COA because it connects the analytical report to a particular production batch.
FDA’s ICH Q7 guidance recommends that certificates of analysis identify the batch or other distinctive code and explains that raw analytical data, graphs, charts, and spectra should be properly identified to show the specific material and batch tested. FDA’s ICH Q7 guidance also states that complete analyses should be periodically compared with supplier certificates to assess their reliability.
For researchers, this means a generic COA reused for multiple batches is less informative than a document clearly linked to the specific batch under evaluation.
When reviewing a peptide certificate of analysis, researchers should look for several basic elements:
Peptide identity: Does the material name match the product being evaluated?
Batch or lot number: Does the number on the COA correspond to the material or packaging?
Testing date: When was the sample analyzed?
Analytical methods: Does the document identify how the reported results were obtained?
HPLC results: Is a numerical purity result provided, and is supporting chromatographic information available?
Mass spectrometry: Is there analytical evidence supporting molecular identity?
Acceptance criteria: Does the COA state the applicable specification or limit alongside the reported result?
Laboratory information: Is the testing organization identified?
These elements are consistent with the information FDA describes for certificates of analysis in ICH Q7.
A COA is valuable, but it does not automatically prove every quality characteristic of a peptide.
For example, a COA showing 99% HPLC purity does not automatically establish sterility, endotoxin status, biological activity, clinical efficacy, or suitability for human administration. Those are separate questions requiring appropriate testing and regulatory evaluation.
This distinction is particularly important because independent research has found discrepancies between supplier-reported peptide quality and laboratory testing. Verbeke et al. (2015) compared supplier information with independent quality-control analyses of synthetic peptides and found that only 44% of the tested peptides met the requested purity in their study; one sample also showed a structure different from the intended peptide.
The study does not mean that every supplier COA is unreliable. Instead, it demonstrates why researchers should examine the method, batch information, analytical evidence, and source of the testing rather than relying on a single headline percentage.
A COA and a specification sheet are not the same document.
A specification describes the requirements or acceptance criteria that a material is expected to meet. A COA reports the analytical results obtained for a particular tested batch. FDA’s ICH Q7 guidance distinguishes specifications and testing from the certificate that documents the results for the relevant batch.
For researchers, confusing these documents can make it difficult to determine whether a reported value is an actual batch result or simply a stated target specification.
For laboratory research, reliable documentation helps researchers determine what material they are working with and supports traceability and reproducibility. A well-documented COA can provide a useful analytical snapshot of a particular batch and help researchers decide whether additional testing may be appropriate for their project.
At Neuro Peptides, we believe researchers should evaluate a COA as part of a broader quality-assessment process rather than treating it as a standalone guarantee. The most useful approach is to examine the product identity, batch information, analytical methods, reported results, and limitations of the testing.
Peptide products discussed in this article are presented for laboratory and scientific research purposes only. They are not intended for human or veterinary use, diagnosis, treatment, cure, mitigation, or prevention of disease.
A Peptide Certificate of Analysis (COA) is a batch-specific analytical document that can provide important information about a research peptide’s identity, reported purity, testing methods, and traceability. HPLC and mass spectrometry provide complementary information, while batch numbers link analytical results to a specific material.
A COA should be read critically. Researchers should verify that the document relates to the relevant batch, understand what each analytical test actually measures, and recognize what the report does not establish.
For Neuro Peptides and the broader research community, the goal is not simply to find the highest reported purity number. It is to understand the quality information behind the number and use appropriate documentation to support responsible, reproducible laboratory research.
A Peptide Certificate of Analysis (COA) is a document that reports analytical testing performed on
Research peptides are laboratory materials intended only for scientific research, while compounded peptides are drug
The FDA issued warning letters to multiple companies in 2026 after reviewing their websites, inspecting
Recent FDA warning letters to peptide companies in 2026 show that products marketed as ‘research
As of September 2026, retatrutide does not have an official commercial release date. Eli Lilly
Retatrutide (LY3437943), developed by Eli Lilly and Company, is an investigational peptide currently not approved